Persantine: profile and news

[an error occurred while processing this directive]

Other information

Indication
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina

Pharmacology
Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.

Mechanism Of Action
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.

Drug Category
Vasodilator Agents; Vasodilator Agents; ATC:B01AC07

Brand Names/Synonyms
Aggrenox; Agilease; Anginal; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apricor; Cardioflux; Cardoxil; Cardoxin; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantyl; Dipiridamol; Dipyridamine; Dipyridamol; Dipyridamole; Dipyridamole, Pharma; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Iv Persantine; Justpertin; Kurantil; Natyl; Novo-Dipiradol; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Prandiol 75; Protangix; RA 8; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12

Dosage Forms
tablets

Absorption
70%

Interactions
Interactions for Dipyridamole:

No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE® (dipyridamole USP) Tablets. The following information was obtained from the literature.

Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.

Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

Chemical IUPAC Name
2-[[3-[bis(2-hydroxyethyl)amino]-5,10-bis(1-piperidyl)-2,4,7,9-tetrazabicyclo[4.4.0]deca-2,4,7,9,11-pentaen-8-yl]-(2-hydroxyethyl)amino]ethanol

Chemical Formula
C24H40N8O4

Half Life
40 minutes

Drug Type
Approved Drug

# Accession No
APRD00360

CAS Registry Number
58-32-2